Antineo
Lyon oncology CRO providing in vitro and in vivo proof-of-concept studies for anticancer agents, including resistant tumor models.
18 contract research organizations in our directory list at least one of Immunotoxicology, Syngeneic Models, Antibody Programs, Cell Therapy, Autoimmune Disease Models, Humanized Mouse Models, Fc Effector Function Assays, Bispecific Antibody Development or Inflammation Models, across 9 countries. 6 report GLP capability and 3 report AAALAC accreditation. Compare their species, services and accreditations below, and contact labs directly from their profiles.
Preclinical immunology work falls into two groups. The first asks whether a drug harms or unintentionally activates the immune system. ICH S8 sets out immunotoxicity assessment, which typically starts with standard toxicology endpoints such as hematology, lymphoid organ weights and histopathology, and adds functional tests such as the T-cell dependent antibody response (TDAR), immunophenotyping by flow cytometry or NK cell activity when there is a signal or a mechanistic concern.
The second group asks whether a drug that targets the immune system works as intended. Immuno-oncology agents need models with a functioning immune system, such as syngeneic tumor models or humanized mice. Antibodies, bispecifics and engineered cell therapies need assays that measure immune cell activation, target engagement and cytokine release, often using human PBMC or whole blood in vitro alongside in vivo work. Autoimmune and inflammatory disease models, such as arthritis, colitis and experimental autoimmune encephalomyelitis, are offered by some labs; ask about them directly.
In vitro immune cell assays are where many immunology programs start. Common examples are T-cell activation, proliferation and cytokine assays; T-cell dependent cellular cytotoxicity (TDCC) for bispecific T-cell engagers; B-cell activation, proliferation and antibody secretion assays; mixed lymphocyte reactions; and antibody effector function assays (ADCC, ADCP and CDC). Most use human PBMC or isolated cells from several donors, so donor variability has to be built into the design, and running the same assay with cynomolgus cells helps support species selection for toxicology.
Flow cytometry capability is a good proxy for depth in this area: ask about panel size, validated species and whether the lab can analyze fresh samples on the day of collection.
Showing 18 CROs. Order rotates daily so no lab is permanently listed first.
Lyon oncology CRO providing in vitro and in vivo proof-of-concept studies for anticancer agents, including resistant tumor models.
Integrated drug discovery CRO in Nottingham with in vivo pharmacology, DMPK and bioanalysis alongside chemistry and biology.
Shanghai-based nonclinical CRO with GLP safety evaluation, pharmacology, DMPK, bioanalysis and biomarker services for small molecules, biologics and cell and gene therapies, operating several sites in China.
Preclinical CRO in Northern Ireland, part of QIMA Life Sciences, running non-GLP rodent PK, dose range finding, biodistribution and disease model studies.
In vivo pharmacology CRO near Philadelphia running a broad catalog of efficacy models across CNS, pain, metabolic and inflammatory disease.
Korean non-clinical CRO focused on efficacy testing of new drug candidates, with research facilities in Songdo, Incheon.
Preclinical efficacy CRO in the Boston area running predictive animal models across inflammation, mucositis, oncology-supportive care and other indications for biotech and pharma sponsors.
Lyon-based company creating genetically engineered and humanized rodent models, with catalog models and in vivo research services.
Beijing-based company providing genetically engineered and humanized mouse models with in vivo pharmacology services, especially for oncology and immunology antibody programs.
Swedish CRO specializing in rodent models of arthritis, autoimmunity and inflammation.
Israeli preclinical CRO offering in vivo pharmacology and disease model studies.
North Carolina CRO specializing in immunotoxicology, including GLP immune function assays for drugs, chemicals and biologics.
French preclinical CRO specializing in bone, joint and inflammatory disease models with histology and imaging readouts.
Independent Danish CRO focused on early in vivo pharmacology in rodents, with particular expertise in mouse cancer and immuno-oncology models.
Preclinical pharmacology CRO in Shanghai with specialty efficacy models in autoimmunity, inflammation, bone and orthopedics, oncology and metabolic disease, plus supporting PK/PD and exploratory toxicology.
Preclinical CRO focused on rodent models of autoimmune and inflammatory disease, such as EAE, arthritis and colitis, with supporting histology, cytokine analysis and flow cytometry.
Biomere (a JOINN company) is a preclinical CRO based in Worcester, MA. Services include non-GLP PK/PD, discovery toxicology, surgical services, disease models, and laboratory sciences. Surgical services include…
Preclinical CRO with GLP laboratories near Budapest and offices in Munich, offering safety assessment, ADME-PK, bioanalysis and pharmacodynamic models.
Preclinical immunology covers two kinds of work: immunotoxicology, which asks whether a drug harms the immune system (ICH S8), and immunopharmacology, which tests drugs that act on it, such as immuno-oncology agents, antibodies, bispecifics and cell therapies. Labs listed here offer at least one of the immunology services we track; check the service tags on each card for the specific capability you need.
Common assays include T-cell activation, proliferation and cytokine release, T-cell dependent cellular cytotoxicity (TDCC) for bispecific T-cell engagers, B-cell activation and antibody secretion, and mixed lymphocyte reactions, usually read out by flow cytometry and multiplex cytokine assays. Ask how many donors each assay uses and whether it can be run with cynomolgus cells as well as human.
For antibodies, the core in vitro immune assays are effector function (ADCC, ADCP and CDC), cytokine release with human PBMC or whole blood, and binding to Fc receptors. Running the same assays with cells from your toxicology species helps show pharmacological relevance. Many European and US labs offer these; use the country shown on each card to narrow by region.